Adastra Holdings (XTXXF) Fair Value & Analysis
Healthcare · US · Market cap $39.2K
Adastra Holdings
XTXXF · US
Fair value as of: Jul 31, 2026
From 10 valuation models · updated 10 days ago
Fair value updated Jul 31, 2026, revised from $0.0086 to $0.0093 (+8.0%) since Jun 26, 2026.
Below-average quality, screening 33% undervalued on our models.
What matters now
- The price is below even our cautious bear case ($0.0093). The market is more pessimistic than our downside scenario.
- Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range ($0.0093 to $0.0170) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.
How to read this chart
60‑month range $0.0070 – $11.69 · fair‑value band $0.0093 – $0.0170 · the $0.0070 price screens below the $0.0093 fair value. Dashed = 300-day average. As of Jul 31, 2026.
Analysis
Adastra Holdings (XTXXF) currently trades at $0.0070, while our model-based Fair Value estimate is $0.0093, implying the stock looks roughly 32.9% undervalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Adastra Holdings generated revenue of $16.9M at a net margin of -85.9%. Revenue declined 33.2% year over year. Net debt stands at $2.3M. Fundamentals as of Jul 31, 2026
Our scenario range runs from $0.0093 (bear case) to $0.0170 (bull case); at $0.0070, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 33%, XTXXF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: Growth DCF ($0.0343) versus Asset-Based ($0.0063). Highest evidence: Growth DCF (80).
Notify me when XTXXF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Adastra Holdings Ltd. extracts and processes cannabis for recreational and medical markets in Canada. The company offers vape pens, wax, resin, infused pre-rolls, diamonds, and shatters under the Endgame brand. It also provides consulting and white label manufacturing. The company was formerly knowns as Phyto Extractions Inc.
Full company description
Adastra Holdings Ltd. extracts and processes cannabis for recreational and medical markets in Canada. The company offers vape pens, wax, resin, infused pre-rolls, diamonds, and shatters under the Endgame brand. It also provides consulting and white label manufacturing. The company was formerly knowns as Phyto Extractions Inc. and changed its name to Adastra Holdings Ltd. in September 2021. Adastra Holdings Ltd. is headquartered in Langley, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Adastra Holdings reported revenue of $24.8M in FY2024 versus $2.5M in FY2020, a compound +77.6%/yr. Reported net income was −$13.2M in FY2024.
Watch XTXXF: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Adastra Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Adastra Holdings (XTXXF) overvalued or undervalued?
What is the fair value of XTXXF?
What is the quality score of XTXXF?
What is the revenue of Adastra Holdings (XTXXF)?
What is the net profit margin of XTXXF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Adastra Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.